Cargando…

Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases

Patients with unresectable hepatic metastases, from uveal or ocular melanoma, are challenging to treat with an overall poor prognosis. Although over the past decade significant advances in systemic therapies have been made, metastatic disease to the liver, especially from uveal melanoma, continues t...

Descripción completa

Detalles Bibliográficos
Autores principales: Carr, Michael J., Sun, James, Cohen, Jonathan B., Liu, Jinhong, Serdiuk, Andrew A., Stewart, Stephen R., Doobay, Navin, Duclos, Andrew, Seal, David A., Choi, Junsung, Zager, Jonathan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480350/
https://www.ncbi.nlm.nih.gov/pubmed/33372814
http://dx.doi.org/10.1177/1073274820983019
_version_ 1784576448867074048
author Carr, Michael J.
Sun, James
Cohen, Jonathan B.
Liu, Jinhong
Serdiuk, Andrew A.
Stewart, Stephen R.
Doobay, Navin
Duclos, Andrew
Seal, David A.
Choi, Junsung
Zager, Jonathan S.
author_facet Carr, Michael J.
Sun, James
Cohen, Jonathan B.
Liu, Jinhong
Serdiuk, Andrew A.
Stewart, Stephen R.
Doobay, Navin
Duclos, Andrew
Seal, David A.
Choi, Junsung
Zager, Jonathan S.
author_sort Carr, Michael J.
collection PubMed
description Patients with unresectable hepatic metastases, from uveal or ocular melanoma, are challenging to treat with an overall poor prognosis. Although over the past decade significant advances in systemic therapies have been made, metastatic disease to the liver, especially from uveal melanoma, continues to be a poor prognosis. Percutaneous hepatic perfusion (PHP) is a safe, viable treatment option for these patients. PHP utilizes high dose chemotherapy delivered directly to the liver while minimizing systemic exposure and can be repeated up to 6 times. Isolation of the hepatic vasculature with a double-balloon catheter allows for high concentration cytotoxic therapy to be administered with minimal systemic adverse effects. A detailed description of the multidisciplinary treatment protocol used at an institution with over 12 years of experience is discussed and recommendations are given. A dedicated team of a surgical or medical oncology, interventional radiology, anesthesiology and a perfusionist allows PHP to be repeatedly performed as a safe treatment strategy for unresectable hepatic metastases.
format Online
Article
Text
id pubmed-8480350
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-84803502021-09-30 Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases Carr, Michael J. Sun, James Cohen, Jonathan B. Liu, Jinhong Serdiuk, Andrew A. Stewart, Stephen R. Doobay, Navin Duclos, Andrew Seal, David A. Choi, Junsung Zager, Jonathan S. Cancer Control Technical Note Patients with unresectable hepatic metastases, from uveal or ocular melanoma, are challenging to treat with an overall poor prognosis. Although over the past decade significant advances in systemic therapies have been made, metastatic disease to the liver, especially from uveal melanoma, continues to be a poor prognosis. Percutaneous hepatic perfusion (PHP) is a safe, viable treatment option for these patients. PHP utilizes high dose chemotherapy delivered directly to the liver while minimizing systemic exposure and can be repeated up to 6 times. Isolation of the hepatic vasculature with a double-balloon catheter allows for high concentration cytotoxic therapy to be administered with minimal systemic adverse effects. A detailed description of the multidisciplinary treatment protocol used at an institution with over 12 years of experience is discussed and recommendations are given. A dedicated team of a surgical or medical oncology, interventional radiology, anesthesiology and a perfusionist allows PHP to be repeatedly performed as a safe treatment strategy for unresectable hepatic metastases. SAGE Publications 2020-12-29 /pmc/articles/PMC8480350/ /pubmed/33372814 http://dx.doi.org/10.1177/1073274820983019 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Technical Note
Carr, Michael J.
Sun, James
Cohen, Jonathan B.
Liu, Jinhong
Serdiuk, Andrew A.
Stewart, Stephen R.
Doobay, Navin
Duclos, Andrew
Seal, David A.
Choi, Junsung
Zager, Jonathan S.
Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases
title Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases
title_full Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases
title_fullStr Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases
title_full_unstemmed Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases
title_short Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases
title_sort over 12 years single institutional experience performing percutaneous hepatic perfusion for unresectable liver metastases
topic Technical Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480350/
https://www.ncbi.nlm.nih.gov/pubmed/33372814
http://dx.doi.org/10.1177/1073274820983019
work_keys_str_mv AT carrmichaelj over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases
AT sunjames over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases
AT cohenjonathanb over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases
AT liujinhong over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases
AT serdiukandrewa over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases
AT stewartstephenr over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases
AT doobaynavin over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases
AT duclosandrew over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases
AT sealdavida over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases
AT choijunsung over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases
AT zagerjonathans over12yearssingleinstitutionalexperienceperformingpercutaneoushepaticperfusionforunresectablelivermetastases